Clair J. Beard, MD
Director, Testicular Cancer Center
Associate Professor of Radiation Oncology, Harvard Medical School
Office phone: 617-732-7948
Preferred contact method: office phone
View Physician Profile
Testicular cancer, Bladder cancer, Advanced prostate cancer, Re-irradiation of the pelvis, Sarcoma
Area of Research
Clinical Research on Testicular Cancer
Brigham and Women's Hospital
75 Francis Street
Tower L2 ASB1
Boston, MA 02215
Dr. Beard is an Associate Professor of Radiation Oncology at Harvard Medical School, Vice-Chair of Genitourinary Radiation Oncology and Director of the Testicular Cancer Center at Dana-Farber/Brigham and Women's Cancer Center. She completed a six-year BS/MD program at Wilkes College and Hahnemann University in 1983 and trained at the Harvard Joint Center for Radiation Therapy. She has been an attending physician since 1989. Her clinical practice emphasizes conformal radiation therapy for prostate and testis cancer and MRT-guided brachytherapy for prostate cancer. In addition, she has a strong interest in patient education, support and advocacy.
As Director of the Testicular Cancer Center, Dr. Beard is working to develop a dedicated surveillance clinic, where patients who do not receive postoperative radiation therapy (RT) for stage I seminoma are rigorously followed, as well as a survivorship clinic, in which treated patients are screened for late effects. The Testicular Cancer Center provides testicular-cancer patients rapid access to specialists, information, support and education.
ResearchClinical Research on Testicular Cancer
As part of a newly formed cancer research consortium, the Late Effects Study Group (LESG), Dr. Beard helped organize and host their first international meeting and collaborated in writing the guidelines for research strategies and recommendations for testicular-cancer survivors. The group is studying genetic predictors of late effects in testicular-cancer survivors. Dr. Beard and colleagues are also investigating the use of prophylactic radiation therapy to treat the draining lymph node areas in the retroperitoneum and pelvis in men with Stage I seminoma. They have conducted two Surveillance, Epidemiology and End Results (SEER) database studies which have identified factors associated with the use of prophylactic RT. Results of the second study, showing an increase in all-cause mortality following prophylactice RT, along with results of a survey study looking at practice patterns and knowledge among American radiation oncologists, were presented at the American Society for Radiation Oncology (ASTRO) national meeting in November, 2010.
Dr. Beard's current projects include a prospective MR-based surveillance protocol for men with Stage I seminoma, a modeling study on radiation exposure to different organs with CT-based surveillance and a collaboration with investigators at Princess Margaret Hospital and Massachusetts General Hospital in a radiation modeling study for Stage II seminoma patients.